PREDICTIVE MODELS FOR RADIATION-INDUCED SIDE EFFECTS IN HEAD AND NECK CANCER BASED ON SINGLE NUCLEOTIDE POLYMORPHISMS (SNP)

PREDICTIVE MODELS FOR RADIATION-INDUCED SIDE EFFECTS IN HEAD AND NECK CANCER BASED ON SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) - HEAD&NECK SNP (HANS) study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50431

Enrollment

2000

Registered

2013-06-18

Start date

2013-09-30

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxiciteit radiotherapie in hoofd-halskanker patiënten normal tissue toxicity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Histological proven head and neck cancer; 2. Primary site in the oral cavity, oropharynx, hypopharynx, nasopharynx, paranasal sinuses, and/or salivary glands; 3. Treatment with curative intent with primary or postoperative radiotherapy either or not combined with systemic treatment; 4. Northern European ethnicity (ethnicity is a known confounder in SNP association studies); 5. Willing and able to comply with the study prescriptions; 6. 18 years or older; 7. No prior radiation (in the head and neck area); 8. Patients must have sufficient knowledge of the Dutch language to understand the meaning of the study as described in the patient information; 9. Have given written informed consent before patient registration.

Exclusion criteria

Exclusion criteria: Prior radiotherapy.

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be RTOG grade 2 or higher late dysphagia.	—

Secondary

Measure	Time frame
The secundary endpoints will be RTOG grade 2 or higher acute dysphagia; acute mucositis; tube feeding dependency; salivary dysfunction (flow); RTOG grade 2-4 acute/late xerostomia; osteoradionecrosis; hypothyroidism; patient-rated head and neck cancer symptoms (EORTC QLQ-H&N35) and; QoL (EORTC QLQ-C30).	—

Countries

Netherlands

Outcome results